SCHEDULE 13G: Alyeska Investment Group Discloses 5.76% Stake in Applied Therapeutics, Including Warrants

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a beneficial ownership of 5.76% in Applied Therapeutics, Inc., comprising common stock and warrants.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 6,707,497 shares of Applied Therapeutics, Inc. common stock.
• This aggregate amount represents 5.76% of the issuer's outstanding common stock.
• The ownership includes 2,707,497 shares of common stock and warrants to purchase an additional 4,000,000 shares.
• The percentage calculation is based on 116,356,474 outstanding shares of common stock, as reported in Applied Therapeutics' 10-Q filing on November 7, 2024.
• The reporting persons hold shared voting and shared dispositive power over all 6,707,497 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant stake by a reputable investment group is generally a neutral to slightly positive signal, indicating institutional interest and confidence in the company, even if it's a passive investment.

Positives

• The disclosure of a significant stake by an investment group like Alyeska could be interpreted as a vote of confidence in Applied Therapeutics, Inc.'s future prospects.
• The acquisition of shares and warrants in the ordinary course of business suggests a strategic investment rather than an activist play, potentially indicating stability.

Future Outlook

The document does not contain any forward-looking statements or guidance from Applied Therapeutics, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.

Industry Context

This filing indicates a significant investment by a prominent investment group in a biotechnology company, which is common in the sector as institutional investors seek exposure to innovative drug development and potential future growth. The nature of the investment (ordinary course of business) suggests a passive stake rather than an attempt to influence corporate strategy, which aligns with typical institutional investment patterns in the biotech industry.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional holder may provide increased confidence or liquidity for the stock. It signals that a major investment group sees value in the company.

Key Dates

Keywords

Applied Therapeutics, Alyeska Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Adviser, Biotechnology, Pharmaceuticals